Posts Tagged ‘Investigational Drug’

Dimebon Clinical Trials

Friday, October 30th, 2009

In regards to Dimebon (Dimbolin) the Medivation firm has announced that it selected the patients for its clinical trial. Does this mean that no other Dimebon will be available for patients until after the trial ends , is published in peer journals and the FDA approves this medication for use in Alzheimer’s Disease ?

Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 ‘CONNECTION’ Trial of Dimebon in Patients With Alzheimer’s Disease

SAN FRANCISCO, June 11, 2009 /PRNewswire-FirstCall via COMTEX News Network/ — Medivation, Inc. (Nasdaq: MDVN) today announced the completion of patient enrollment in the CONNECTION study, a six-month, confirmatory, pivotal Phase 3 trial of the investigational drug dimebon in patients with mild-to-moderate Alzheimer’s disease.

The international, double-blind, placebo-controlled, pivotal Phase 3 study enrolled 598 patients, exceeding the enrollment target of 525 patients. More than 40 percent of the patients enrolled were in the United States. The six-month study is evaluating the effect of dimebon on the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) and the Clinician’s Interview-Based Impression of Change plus caregiver interview (CIBIC-plus) — the two endpoints have historically been accepted by the U.S. Food and Drug Administration (FDA) to support registration of currently approved drugs for mild-to-moderate Alzheimer’s disease.

“Completion of patient enrollment in this second pivotal trial moves us closer to our goal of submitting a marketing application to the FDA and bringing dimebon to market for the many Alzheimer’s patients suffering from this devastating disease,” said Lynn Seely, M.D., chief medical officer of Medivation. “We are gratified by the strong interest in this trial as indicated by our exceeding the enrollment goal. Together with our partner Pfizer, we are executing a comprehensive clinical plan to support an NDA filing, currently targeted for 2011, with a broad and differentiated label for dimebon in Alzheimer’s disease. We are also conducting a Phase 3 safety study, which will provide us and Pfizer the opportunity to seek marketing approval earlier if results of the CONNECTION study confirm our previously completed first pivotal study, which was published in the Lancet last year.”

About Dimebon

Dimebon is an investigational compound currently in Phase 3 development for the treatment of Alzheimer’s disease and in clinical development for Huntington disease. In preclinical models of Alzheimer’s disease and Huntington disease explored thus far, dimebon has been shown to inhibit brain cell death, potentially by stabilizing and improving mitochondrial function in a way that prevents neuron death and dysfunction. The dimebon mechanism is thought to be distinct from that of currently available Alzheimer’s disease medications.

In addition to CONNECTION, dimebon is being studied in the 12-month Phase 3 CONCERT trial, which is evaluating the efficacy of dimebon when added to ongoing treatment with donepezil (Aricept(R)) in patients with mild-to-moderate Alzheimer’s disease, and in a Phase 3 safety study. Two Phase 3 studies in moderate-to-severe Alzheimer’s disease are also planned to start this year.

In Huntington disease, a Phase 2 study has been completed. Medivation and Pfizer expect to initiate a Phase 3 trial this year to evaluate the potential benefits of dimebon on cognition in patients with Huntington disease.

About Alzheimer’s Disease

Alzheimer’s disease is a progressive degenerative brain disorder that gradually destroys a person’s memory and ability to learn, reason, make judgments, communicate and carry out daily activities. As the disease progresses, patients may experience changes in personality and behavior, such as anxiety, suspiciousness or agitation, as well as delusions or hallucinations.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize dimebon for the treatment of Alzheimer’s and Huntington diseases. With Pfizer, the Company is conducting a broad dimebon clinical development program that includes several Phase 3 trials assessing the efficacy and safety of dimebon taken alone or in combination with other Alzheimer’s medications in patients with mild, moderate or severe Alzheimer’s disease. Further development of dimebon in patients with Huntington disease is also planned. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing, and a Phase 3 trial is expected to begin this year. For more information, please visit us at http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding the timing and potential results of clinical trials, and the anticipated timing of regulatory filings, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Medivation’s actual results to differ significantly from those projected, including, without limitation, risks related to progress, timing and results of Medivation’s clinical trials, difficulties or delays in obtaining regulatory approval, enrollment of patients in Medivation’s clinical trials, partnering of Medivation’s product candidates, manufacturing of Medivation’s product candidates, competition with Medivation’s product candidates should they receive marketing approval, the adequacy of Medivation’s financial resources, unanticipated expenditures or liabilities, intellectual property matters, and other risks detailed in Medivation’s filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q for the quarter ended March 31, 2009, filed on May 11, 2009, with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Medivation disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.

SOURCE Medivation, Inc.

Dimebon Alzheimer’s Disease

http://www.dimebonalzheimers.com

  • Share/Bookmark
Blog Traffic Exchange Related Websites

Tags: , , , , , , , , , , , , , , , , , , ,
Posted in Uncategorized | No Comments »

Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer

Thursday, October 29th, 2009

– Medivation to Receive $110 Million Upfront Cash Payment and Eligible to Receive $655 Million in Milestone Payments, 50 Percent of U.S. Profits and Double-Digit Royalties on Ex-U.S. Sales — – Medivation to Host Conference Call/Webcast Today at 8:30 a.m. Eastern Time –

TOKYO and SAN FRANCISCO, Oct. 27 /PRNewswire-FirstCall/ — Astellas Pharma Inc. (“Astellas”) and Medivation, Inc. (Nasdaq: MDVN) announced today that they have entered into a global agreement to develop and commercialize MDV3100, Medivation’s investigational drug for the treatment of prostate cancer. MDV3100 is currently being evaluated in the Phase 3 AFFIRM clinical trial in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.

Under the terms of the agreement, Medivation will receive an up-front cash payment of $110 million. Medivation is also eligible to receive payments of up to $335 million upon the attainment of development and regulatory milestones plus up to an additional $320 million in commercial milestone payments. The companies will collaborate on a comprehensive development program that will include additional studies to develop MDV3100 for both late- and early-stage prostate cancer. Subject to receipt of regulatory approval, the companies will jointly commercialize MDV3100 in the U.S. The companies will share equally all U.S. development costs, commercialization costs, and profits. Astellas will have responsibility for developing and commercializing MDV3100 outside the U.S. and will pay Medivation tiered double-digit royalties on ex-U.S. sales.

“We are pleased to initiate a great partnership with Medivation,” stated Masafumi Nogimori, president and chief executive officer of Astellas. “We believe that MDV3100 has the unique potential to establish a new treatment approach for prostate cancer. Astellas already has the global expertise in urology and the strong commitment to focus on oncology. This partnership is a significant milestone to further expand our business in urology and to establish our franchise in oncology.”

“We are excited to be working with Astellas to develop MDV3100 for a broad spectrum of prostate cancer disease states,” said David Hung, M.D., president and chief executive officer of Medivation. “Astellas is an ideal partner for MDV3100 given its global reach, leading commercial presence in the urology space, and strategic focus on oncology. Astellas is the second major collaboration we have completed in the past year, and we are confident we have the right partners in place for each of our late-stage programs–Astellas for MDV3100 and Pfizer, Inc for dimebon (latrepirdine*).”

According to the American Cancer Society, prostate cancer is the most common non-skin cancer among men in the United States. More than 2 million American men have prostate cancer, and it is the second leading cause of cancer death among men after lung cancer. In 2009, an estimated 192,000 new cases are expected to be diagnosed, and approximately 27,000 men are expected to die from the disease.

MDV3100, a new generation of oral anti-androgen, which shows different pharmacological profiles from current anti-androgens, has been shown in preclinical studies to provide more complete suppression of the androgen receptor pathway than bicalutamide, the most commonly used anti-androgen. MDV3100 slows growth and induces cell death in bicalutamide-resistant cancers via three complementary actions – MDV3100 blocks testosterone binding to the androgen receptor, impedes movement of the androgen receptor to the nucleus of prostate cancer cells (nuclear translocation), and inhibits binding to DNA. Preclinical data published in Science earlier this year demonstrated that MDV3100 is superior to bicalutamide in each of these three actions.

The agreement is not subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and becomes effective immediately. Medivation’s legal and financial advisers on the transaction were Cooley Godward Kronish LLP and Aquilo Partners, L.P. Astellas’ legal adviser on the transaction was Covington & Burling LLP.

*Latrepirdine is the proposed generic (nonproprietary) name for dimebon.

Conference Call Information
Medivation will hold a conference call today at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss this announcement. To participate in the conference call, please dial 888-280-4443 for domestic callers and 1-719-457-2638 for international callers. In addition, this call is being Webcast and can be accessed at Medivation’s website at www.medivation.com.

About MDV3100′s Clinical Program
In September 2009, Medivation began enrolling patients in a randomized, placebo-controlled, double-blind, multi-national Phase 3 clinical trial known as AFFIRM. This trial is evaluating MDV3100 at a dose of 160 mg taken orally once daily versus placebo in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy. The primary endpoint of the trial is overall survival; secondary endpoints include progression-free survival, safety and tolerability. This trial is expected to enroll approximately 1,200 patients at sites in the United States, Canada, Europe, South America, Australia and South Africa.

Medivation previously announced interim safety and efficacy results from an ongoing Phase 1-2 clinical trial of MDV3100. The interim results showed that MDV3100 was associated with anti-tumor activity in patients who had become resistant to bicalutamide or other standard anti-androgen treatments, including both patients who had failed prior chemotherapy and patients who were chemotherapy naive. Anti-tumor activity was demonstrated by reductions in prostate-specific antigen levels, improvement or stabilization in tumors that had spread to soft tissue or bone, and a decrease in circulating tumor cells, which has been associated in published literature with improved survival in patients with castration-resistant prostate cancer. MDV3100 was generally well tolerated in this trial at doses up to and including 240 mg/day, with fatigue being the most frequently reported adverse event.

About Astellas
Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 14,000 employees worldwide. The organization is committed to becoming a global category leader in Urology, Immunology and Inflammatory, Diabetes, CNS/Pain, Infectious diseases (virus) and Cancer. For more information on Astellas Pharma Inc., please visit our website at http://www.astellas.com.

About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer, Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer’s and Huntington diseases. With Pfizer, Medivation is conducting a broad dimebon clinical development program that includes several Phase 3 trials assessing the efficacy and safety of dimebon taken alone or in combination with other Alzheimer’s medications in patients with mild, moderate and severe Alzheimer’s disease. The companies are also conducting a Phase 3 trial of dimebon in Huntington disease. In October 2009, Medivation entered a global agreement with Astellas Pharma Inc. to develop and commercialize MDV3100 for prostate cancer. The first Phase 3 clinical trial in the MDV3100 development program, known as the AFFIRM trial, is under way in patients with castration-resistant prostate cancer who have previously been treated with docetaxel-based chemotherapy. For more information, please visit us at http://www.medivation.com.

Medivation Forward Looking Statement
This press release contains forward-looking statements, including statements related to future clinical development of and ongoing clinical trials evaluating MDV3100, the therapeutic and commercial potential of MDV3100, and potential future development and regulatory milestone payments, commercial milestone payments and royalty payments under the agreement with Astellas, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Medivation’s actual results to differ significantly from those projected, including, without limitation, risks related to the progress, timing and results of Medivation’s clinical trials, including the risk that positive results in earlier clinical trials may not be repeated in subsequent clinical trials and the risk that interim results from ongoing clinical trials may not be predictive of the final results of any such trial, enrollment of patients in Medivation’s clinical trials, difficulties or delays in obtaining regulatory approvals, Medivation’s dependence on Astellas for aspects of the development, regulatory approval, manufacturing and commercialization of MDV3100, manufacturing of MDV3100, competition with MDV3100 should it receive marketing approvals, the adequacy of Medivation’s financial resources, unanticipated expenditures or liabilities, intellectual property matters, and other risks detailed in Medivation’s filings with the Securities and Exchange Commission (SEC), including its quarterly report on Form 10-Q for the quarterly period ended June 30, 2009, filed with the SEC on August 5, 2009. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Medivation disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.

SOURCE Medivation, Inc.

http://www.earthtimes.org/articles/show/astellas-and-medivation-enter-into,1015012.shtml

Dimebon Alzheimer’s Disease

http://www.dimebonalzheimers.com

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • Books: Get Your Motivation Back! With January over, many people will be either be well on the way to making their new years resolutions or have already ditched them. If you're part of the first...
  • Dr. Vipul Patel at Celebration Health Dr. Vipul Patel: A World Renowned Robotic Prostate Cancer Surgeon Robotic Prostatectomy is gaining more and more popularity over conventional surgery.  With traditional surgery, the incision is between eight to ten...
  • Cancer Cure? Green Tea! Here is another one of those forwarded emails that I want my readers to read because it is very beneficial to everyone. Once again, it is about cancer. And since...
  • Nanotech Robots Developed to Fight Cancer [/caption] On Sunday, March 21, 2010, a group of United States researchers released their findings in the journal Nature. The study offers early proof that a new treatment approach of...
  • Learning More About Promoting Prostate Cancer Awareness Getting identified as having most cancers is a tough encounter. Prostate cancer patients may experience main depression. It's even more tough to take especially if you find absolutely no presently...
  • Treatment of Breast Cancer Following a breast cancer diagnosis, you are going to need to sit down with your doctors so that you can put together a unique treatment plan. It is important that...
  • Green Tea slows prostate cancer There is evidence that the polyphenols found in green tea may slow the progression of prostate cancer, according to a study published recently in Cancer Prevention Research,[2. McLarty et al....

Tags: , , , , , , , , , , , , , , , , , , ,
Posted in Uncategorized | No Comments »

Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer

Thursday, October 29th, 2009

Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and
Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
– Medivation to Receive $110 Million Upfront Cash Payment and Eligible to
Receive $655 Million in Milestone Payments, 50 Percent of U.S. Profits and
Double-Digit Royalties on Ex-U.S. Sales –

TOKYO and SAN FRANCISCO, Oct. 27 /PRNewswire-FirstCall/ — Astellas Pharma
Inc. (“Astellas”) and Medivation, Inc. (Nasdaq: MDVN) announced today that
they have entered into a global agreement to develop and commercialize
MDV3100, Medivation’s investigational drug for the treatment of prostate
cancer. MDV3100 is currently being evaluated in the Phase 3 AFFIRM clinical
trial in men with castration-resistant prostate cancer who were previously
treated with docetaxel-based chemotherapy.

Under the terms of the agreement, Medivation will receive an up-front cash
payment of $110 million. Medivation is also eligible to receive payments of
up to $335 million upon the attainment of development and regulatory
milestones plus up to an additional $320 million in commercial milestone
payments. The companies will collaborate on a comprehensive development
program that will include additional studies to develop MDV3100 for both late-
and early-stage prostate cancer. Subject to receipt of regulatory approval,
the companies will jointly commercialize MDV3100 in the U.S. The companies
will share equally all U.S. development costs, commercialization costs, and
profits. Astellas will have responsibility for developing and commercializing
MDV3100 outside the U.S. and will pay Medivation tiered double-digit royalties
on ex-U.S. sales.

“We are pleased to initiate a great partnership with Medivation,” stated
Masafumi Nogimori, president and chief executive officer of Astellas. “We
believe that MDV3100 has the unique potential to establish a new treatment
approach for prostate cancer. Astellas already has the global expertise in
urology and the strong commitment to focus on oncology. This partnership is a
significant milestone to further expand our business in urology and to
establish our franchise in oncology.”

“We are excited to be working with Astellas to develop MDV3100 for a broad
spectrum of prostate cancer disease states,” said David Hung, M.D., president
and chief executive officer of Medivation. “Astellas is an ideal partner for
MDV3100 given its global reach, leading commercial presence in the urology
space, and strategic focus on oncology. Astellas is the second major
collaboration we have completed in the past year, and we are confident we have
the right partners in place for each of our late-stage programs–Astellas for
MDV3100 and Pfizer, Inc for dimebon (latrepirdine*).”

According to the American Cancer Society, prostate cancer is the most common
non-skin cancer among men in the United States. More than 2 million American
men have prostate cancer, and it is the second leading cause of cancer death
among men after lung cancer. In 2009, an estimated 192,000 new cases are
expected to be diagnosed, and approximately 27,000 men are expected to die
from the disease.

MDV3100, a new generation of oral anti-androgen, which shows different
pharmacological profiles from current anti-androgens, has been shown in
preclinical studies to provide more complete suppression of the androgen
receptor pathway than bicalutamide, the most commonly used anti-androgen.
MDV3100 slows growth and induces cell death in bicalutamide-resistant cancers
via three complementary actions – MDV3100 blocks testosterone binding to the
androgen receptor, impedes movement of the androgen receptor to the nucleus of
prostate cancer cells (nuclear translocation), and inhibits binding to DNA.
Preclinical data published in Science earlier this year demonstrated that
MDV3100 is superior to bicalutamide in each of these three actions.

The agreement is not subject to approval under the Hart-Scott-Rodino Antitrust
Improvements Act of 1976 and becomes effective immediately. Medivation’s
legal and financial advisers on the transaction were Cooley Godward Kronish
LLP and Aquilo Partners, L.P. Astellas’ legal adviser on the transaction was
Covington & Burling LLP.

*Latrepirdine is the proposed generic (nonproprietary) name for dimebon.

Conference Call Information
Medivation will hold a conference call today at 8:30 a.m. Eastern Time (5:30
a.m. Pacific Time) to discuss this announcement. To participate in the
conference call, please dial 888-280-4443 for domestic callers and
1-719-457-2638 for international callers. In addition, this call is being
Webcast and can be accessed at Medivation’s website at www.medivation.com.

About MDV3100′s Clinical Program
In September 2009, Medivation began enrolling patients in a randomized,
placebo-controlled, double-blind, multi-national Phase 3 clinical trial known
as AFFIRM. This trial is evaluating MDV3100 at a dose of 160 mg taken orally
once daily versus placebo in men with castration-resistant prostate cancer who
were previously treated with docetaxel-based chemotherapy. The primary
endpoint of the trial is overall survival; secondary endpoints include
progression-free survival, safety and tolerability. This trial is expected to
enroll approximately 1,200 patients at sites in the United States, Canada,
Europe, South America, Australia and South Africa.

Medivation previously announced interim safety and efficacy results from an
ongoing Phase 1-2 clinical trial of MDV3100. The interim results showed that
MDV3100 was associated with anti-tumor activity in patients who had become
resistant to bicalutamide or other standard anti-androgen treatments,
including both patients who had failed prior chemotherapy and patients who
were chemotherapy naive. Anti-tumor activity was demonstrated by reductions in
prostate-specific antigen levels, improvement or stabilization in tumors that
had spread to soft tissue or bone, and a decrease in circulating tumor cells,
which has been associated in published literature with improved survival in
patients with castration-resistant prostate cancer. MDV3100 was generally well
tolerated in this trial at doses up to and including 240 mg/day, with fatigue
being the most frequently reported adverse event.

About Astellas
Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company
dedicated to improving the health of people around the world through the
provision of innovative and reliable pharmaceuticals. Astellas has
approximately 14,000 employees worldwide. The organization is committed to
becoming a global category leader in Urology, Immunology and Inflammatory,
Diabetes, CNS/Pain, Infectious diseases (virus) and Cancer. For more
information on Astellas Pharma Inc., please visit our website at

http://www.astellas.com.

About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid
development of novel small molecule drugs to treat serious diseases for which
there are limited treatment options. Medivation aims to transform the
treatment of these diseases and offer hope to critically ill patients and
their caregivers. In September 2008, Medivation announced a global agreement
with Pfizer, Inc to develop and commercialize dimebon (latrepirdine) for the
treatment of Alzheimer’s and Huntington diseases. With Pfizer, Medivation is
conducting a broad dimebon clinical development program that includes several
Phase 3 trials assessing the efficacy and safety of dimebon taken alone or in
combination with other Alzheimer’s medications in patients with mild, moderate
and severe Alzheimer’s disease. The companies are also conducting a Phase 3
trial of dimebon in Huntington disease. In October 2009, Medivation entered a
global agreement with Astellas Pharma Inc. to develop and commercialize
MDV3100 for prostate cancer. The first Phase 3 clinical trial in the MDV3100
development program, known as the AFFIRM trial, is under way in patients with
castration-resistant prostate cancer who have previously been treated with
docetaxel-based chemotherapy. For more information, please visit us at

http://www.medivation.com.

Medivation Forward Looking Statement
This press release contains forward-looking statements, including statements
related to future clinical development of and ongoing clinical trials
evaluating MDV3100, the therapeutic and commercial potential of MDV3100, and
potential future development and regulatory milestone payments, commercial
milestone payments and royalty payments under the agreement with Astellas,
which are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Any statements contained in this
press release that are not statements of historical fact may be deemed to be
forward-looking statements. Forward-looking statements involve risks and
uncertainties that could cause Medivation’s actual results to differ
significantly from those projected, including, without limitation, risks
related to the progress, timing and results of Medivation’s clinical trials,
including the risk that positive results in earlier clinical trials may not be
repeated in subsequent clinical trials and the risk that interim results from
ongoing clinical trials may not be predictive of the final results of any such
trial, enrollment of patients in Medivation’s clinical trials, difficulties or
delays in obtaining regulatory approvals, Medivation’s dependence on Astellas
for aspects of the development, regulatory approval, manufacturing and
commercialization of MDV3100, manufacturing of MDV3100, competition with
MDV3100 should it receive marketing approvals, the adequacy of Medivation’s
financial resources, unanticipated expenditures or liabilities, intellectual
property matters, and other risks detailed in Medivation’s filings with the
Securities and Exchange Commission (SEC), including its quarterly report on
Form 10-Q for the quarterly period ended June 30, 2009, filed with the SEC on
August 5, 2009. You are cautioned not to place undue reliance on the
forward-looking statements, which speak only as of the date of this press
release. Medivation disclaims any obligation or undertaking to update or
revise any forward-looking statements contained in this press release.

SOURCE Medivation, Inc.

Patrick Machado, Chief Financial Officer of Medivation, +1-415-829-4101; or
Corporate Communications of Astellas Pharma Inc., +81-3-3244-3201, Fax:
+81-3-5201-7473

http://www.reuters.com/article/pressRelease/idUS121460+27-Oct-2009+PRN20091027

  • Share/Bookmark
Blog Traffic Exchange Related Websites

Tags: , , , , , , , , , , , , , , , , , , ,
Posted in Uncategorized | No Comments »

Donepezil

Monday, April 20th, 2009

Donepezil (Aricept)  is a drug derived from components of actual black pepper.  It is the most widely prescribed drug for patients who have Alzheimer’s disease .  It works by preventing the breakdown of the chemical neurotransmitter acetylcholine in the brain.  The tablet is taken once daily , which helps with regular pill taking  ( compliance).  It seems that for all the studies that have been done in an effort to improve the taking of pills and medications on a regular basis – that is compliance – that lack of compliance is generally estimated at a full 50 %.   The only things that seem to enhance and improve compliance levels with medications are 1) to reduce the frequency of dosage and 2) tie in the pill taking to a regime involving a daily habit — 0ften meals.   To make matters perhaps more amusing and even worse it seems that patients often improve their regular pill taking and compliance of medications when they become more ill and are reminded of their symptoms.  The poor health care providers are often at a loss to explain symptoms and side effects that often and usually were not present before and are the direct result of patients now taking their pills and medications on a regular and proper basis. On top of that multi-drug side effects and interactions may now emerge since the patient may well be finally taking the drugs they had forgot to or had chosen not to take before in their treatment plan and plans.

Forteo, Enbrel, Methotrexate, Folic Acid, Donepezil Hcl … – Large, long term drug study: Forteo, Enbrel, Methotrexate, Folic Acid, Donepezil Hcl, Hydrocodone Bitartrate And Acetaminophen, Acetylsalicylic Acid Srt drug interactions and effectivenesses for females and males at all ages (2742948)

Phase 3 study of Dimebon and donepezil combination therapy for … – Pfizer and Medivation, Inc announced the initiation of a 12-month, Phase 3 trial of the investigational drug Dimebon in combination with donepezil HCl for the treatment of mild-to-moderate Alzheimer’s disease (AD).

Alzheimer’s Reading Room: Dimebon Added to Donepezil in Patients … – The study builds on data from a small-scale safety and tolerability trial of Dimebon added to donepezil, which found the combination to be well tolerated. CONCERT is designed to complement previous and ongoing studies by further …

Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to … – New 12-month study broadens Phase 3 clinical program to further eval… …NEW YORK and SAN FRANCISCO April 15 /- Pfizer … …,Pfizer,and,Medivation,Initiate,Phase,3,Trial,of,Dimebon,Added,to,Donepezil,in,Patients,with,Alzheimer’s …

Drug interactions analysis of Zyprexa, Venlafaxine Hcl … – Real world drug safety study: Drug interactions analysis of Zyprexa, Venlafaxine Hcl, Risperidone, Quetiapine, Donepezil Hcl (2704001) … Donepezil Hcl. ^Back to Content. 2 related incidents are studied for males aged 75 (±5): …

Donepezil – Welcome to donepezil WebLog donepezil BUY ONLINE! Related Posts: {RELATED}. EPIX Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly …

Donepezil – Darkover has butorphanol opiate withdrawal features once crooning under heal children fulvicin always said smoke from trigger breathing relenza market share gsk hat about with all too was aricept donepezil hydrochloride omilla and …

Donepezil Hcl side effects and drug interactions analysis (ID … – Drug(s): Donepezil Hcl Date: Aug, 28, 2008 Patient demographics: unspecified year(s) old Male who has Cognitive Disorder.

 

The Donepezil comes in tablet form.   The typical daily dose id 10 mg. It is generally well tolerated.  Often the dose is started low at 5 mg per a day and then “bumped” up to the 10 mg dose.    Some authorities and practitioners in the field have believed that the drug will only work for a six month time period whereas others have continued treatment with the drug and made substantiated claims that a beneficial effect can be demonstrated in Alzheimer’s patients for several years. Indeed the medication may have  a disease modifying and limited beneficial effect all on its own.

Dimebon Alzheimer?s Disease

http://www.dimebonalzheimers.com

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • Oral diabetes drug, Avandia, may greatly increase risk of heart attack Patients taking Avandia, an oral diabetes drug from GlaxoSmithKline, proved 43 percent more likely to have heart attacks according to a recent study published in the New England Journal of...
  • Manny and Brett It was a great sports day for me. Two of my least favorite sports figures made the news. The twice retired quarterback Brett Favre told my Minnesota Vikings that he...
  • Review: If I'm So Smart, Why Can't I Lose Weight? - Tools to Get it Done According to Brooke Castillo, author of this book, intelligent and accomplished men and women often have intense difficulty losing weight and getting healthy. One of the main reasons that it...
  • US Patients Battle the FDA Over Use of Their Own Cells Image via Wikipedia American Doctors and Patients Challenge the FDA to Save Lives Rather Than Allow Patients to Needlessly Die A couple of weeks ago, the American Stem Cell Therapy...
  • OnPar Golf Touchscreen GPS User Reviews Send this to a friend OnPar Golf Touchscreen GPS Manufacturer: OnPar Customer Rating: List Price: $479.95 Sale Price: $319.99 Availibility: Usually ships in 1-2 business days Buy Now...
  • Save Money on Medicine [/caption]I haven't mentioned it in a long-time, but in former life (we are going back to my high school and college years), I was a pharmacy technician. I found it...
  • A U.S. Supreme Court Justice Speaks on Behalf of Alzheimer's Patients Families and caregivers of Alzheimer's patients have a strong ally  in retired U.S. Supreme Court Justice Sandra Day O'Conner. Her husband John has Alzheimer's and she understands the difficulties of caregiving ...

Tags: , , , , , , , , , , , , , , , , , , ,
Posted in Uncategorized | No Comments »